NCT03001154

Brief Summary

Virtual Reality Exposure Therapy (VRET) is an efficacious treatment of fear and anxiety, but because of the high financial costs and technical complexity of the past generation of VR hardware, there has been no large-scale implementation of this promising treatment. The present study will investigate whether off-the-shelf, commercial VR hardware and software can be used as stimuli material to conduct in-session exposure therapy for speech anxiety. The study will recruit n=25+25 participants from the general public suffering from substantial speech anxiety, who will be randomized to either a waiting-list, or one-session VRET with a therapist, followed by four weeks of a progressive maintenance program encouraging in-vivo exposure. The waiting-list group will then receive an Internet-delivered VRET treatment program.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 20, 2016

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 22, 2016

Completed
10 days until next milestone

Study Start

First participant enrolled

January 1, 2017

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2017

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2018

Completed
Last Updated

March 7, 2019

Status Verified

March 1, 2019

Enrollment Period

4 months

First QC Date

December 20, 2016

Last Update Submit

March 6, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Public Speaking Anxiety Scale

    Self-rating of public speaking anxiety

    Change from baseline: Week 0, 1, 2, 3, 4, 5 and 21

Secondary Outcomes (5)

  • Liebowitz Social Anxiety Scale Self-Report

    Change from baseline: Week 0, 5 and 21

  • Brief Fear of Negative Evaluation Scale

    Change from baseline: Week 0, 5 and 21

  • Patient Health Questionnaire 9-item

    Change from baseline: Week 0, 5 and 21

  • Generalized Anxiety Disorder 7-item

    Change from baseline: Week 0, 5 and 21

  • Brunnsviken Brief Quality of life scale

    Change from baseline: Week 0, 5 and 21

Study Arms (2)

One-session VRET face-to-face

EXPERIMENTAL

One-session Virtual Reality Exposure Therapy led by therapist (face-to-face), followed by a 4-week therapist-guided Internet-administered progressive maintenance program.

Behavioral: Face-to-face Virtual Reality Exposure Therapy

Waiting-list, then Internet-administered VRET

EXPERIMENTAL

4-week waiting list, followed by therapist-guided, Internet-administered VRET with a 4-week progressive maintenance program.

Behavioral: Internet-administered Virtual Reality Exposure TherapyOther: Waiting-list

Interventions

In session, systematic, hierarchical exposure to feared stimuli with therapist.

One-session VRET face-to-face

Therapist-guided, Internet-administered Virtual Reality Exposure Therapy self-help program

Waiting-list, then Internet-administered VRET

Weekly assessments of public speaking

Waiting-list, then Internet-administered VRET

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Substantial public speaking anxiety
  • Have access to VR-compatible smartphone (including Internet)
  • Can travel to Stockholm University for treatment on one occasion
  • Can speak and understand sufficient Swedish

You may not qualify if:

  • Deficits in sight or balance impacting the VR-experience
  • A severe psychiatric disorder better treated elsewhere, including current major depression, alcohol or drug abuse, bipolarity, psychosis or similar
  • Active psychopharmacological treatment, unless stable for last 3 months
  • Other ongoing psychological treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Psychology

Stockholm, 10691, Sweden

Location

MeSH Terms

Conditions

Phobia, SocialAnxiety Disorders

Interventions

Waiting Lists

Condition Hierarchy (Ancestors)

Phobic DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Appointments and SchedulesOrganization and AdministrationHealth Services Administration

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

December 20, 2016

First Posted

December 22, 2016

Study Start

January 1, 2017

Primary Completion

May 1, 2017

Study Completion

June 1, 2018

Last Updated

March 7, 2019

Record last verified: 2019-03

Locations